EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Parental acceptability of newborn screening expansion in the genomic era: A nationwide French survey informed by the Theoretical Framework of Acceptability (SeDeN-p3)

Camille Level iD, Laurence Faivre, Margot Lemaitre, Dominique Salvi, Isabelle Marchetti-Waternaux, Elisabeth Cudry, Emmanuel Simon, Nicolas Bourgon, Alexandra Benachi, Nhut-Thanh Van, Camille Coppola, Christine Binquet und 3 weitere

PLOS One · 15.06.2026 · 21 (6) · e0343754

DOI: 10.1371/journal.pone.0343754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 15.06.2026. Verfasst von Camille Level und 14 weiteren Autor:innen. Beteiligte Einrichtung: Université Bourgogne Europe, Dijon, France. Hauptthemen laut MEDLINE: Neonatal Screening, Parents, Genomics, Patient Acceptance of Health Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi Winthrop Industrie, Kyowa Kirin Pharmaceutical Development, Pole Fédératif de Recherche et de Formation en Santé Publique Bourgogne Franche Comté.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Newborn screening (NBS) has progressively expanded through technological innovations, from tandem mass spectrometry enabling expanded NBS (eNBS) to the prospect of genomic NBS (gNBS). While these developments promise earlier diagnosis and richer information, they also raise concerns regarding actionability, uncertainty, equity and psychosocial impact. As technological feasibility alone does not ensure public confidence, parental perspectives are central to evaluating future expansions. This study assessed parental views on NBS expansion in France, examining its determinants and whether genomics raises specific concerns.

Methods

A nationwide cross-sectional survey (September 2022–February 2023) included 1,640 parents recruited postpartum in maternity wards and through an online quota panel. Acceptability of eNBS and gNBS was assessed alongside intermediate components from the Theoretical Framework of Acceptability (affective attitude, perceived effectiveness, ethicality), a technical trade-off scenario, and individual characteristics. Analyses combined descriptive statistics, multivariable regression, and thematic analysis of free-text comments.

Results

Support was very high for eNBS (93%) and remained high for gNBS (89%), with genetics mainly shifting responses from complete to partial acceptability. Affective attitude and perceived effectiveness were the strongest predictors of both outcomes, while ethical concerns distinguished assured from conditional support. Most parents prioritised minimising uncertain results, whereas a smaller subgroup accepted greater ambiguity. Foreign-born and single parents reported lower levels of complete acceptability, while health-sector workers and parents with rare-disease experience were more supportive. No independent association with the age of the youngest child was observed.

Conclusion

Parental acceptability of eNBS and gNBS is high but nuanced, shaped primarily by anticipated health benefits, emotional orientation and tolerance for uncertainty, with trust and social distance modulating support. As genomic expansion progresses, implementation will require proportionate, culturally adapted information and clear governance, and should be informed by real-world evidence from pilots such as PERIGENOMED.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neonatal ScreeningParentsGenomicsPatient Acceptance of Health CareHumansFranceInfant, NewbornFemaleSurveys and QuestionnairesCross-Sectional StudiesAdultMale

Autor:innen und Institutionen

  • Université Bourgogne Europe, Dijon, France.
  • Fédération Hospitalo-Universitaire TRANSLAD, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France.
  • Centre de Génétique, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France.
  • Association Valentin des Porteurs d'Anomalies Chromosomiques, Eragny sur Oise, France.
  • Association Vaincre les Maladies Lysosomales, Massy, France.
  • Maternité, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France.

ORCID-Profile: Camille Level, Christine Peyron

Förderung

  • Sanofi Winthrop Industrie
  • Kyowa Kirin Pharmaceutical Development
  • Pole Fédératif de Recherche et de Formation en Santé Publique Bourgogne Franche Comté

Zitieren

APA

Level, C., Faivre, L., Lemaitre, M., Salvi, D., Marchetti-Waternaux, I., Cudry, E., Simon, E., Bourgon, N., Benachi, A., Van, N. T., Coppola, C., Binquet, C., Thauvin-Robinet, C., Huet, F., & Peyron, C. (2026). Parental acceptability of newborn screening expansion in the genomic era: A nationwide French survey informed by the Theoretical Framework of Acceptability (SeDeN-p3). PLOS One, 21(6), e0343754. https://doi.org/10.1371/journal.pone.0343754

Vancouver

Level C, Faivre L, Lemaitre M, Salvi D, Marchetti-Waternaux I, Cudry E, et al. Parental acceptability of newborn screening expansion in the genomic era: A nationwide French survey informed by the Theoretical Framework of Acceptability (SeDeN-p3). PLOS One. 2026;21(6):e0343754. doi:10.1371/journal.pone.0343754

BibTeX
@article{Level2026,
  author = {Level, Camille and Faivre, Laurence and Lemaitre, Margot and Salvi, Dominique and Marchetti-Waternaux, Isabelle and Cudry, Elisabeth and Simon, Emmanuel and Bourgon, Nicolas and Benachi, Alexandra and Van, Nhut-Thanh and Coppola, Camille and Binquet, Christine and Thauvin-Robinet, Christel and Huet, Frédéric and Peyron, Christine},
  title = {Parental acceptability of newborn screening expansion in the genomic era: A nationwide French survey informed by the Theoretical Framework of Acceptability (SeDeN-p3)},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0343754},
  doi = {10.1371/journal.pone.0343754}
}
Kostenlos starten →